Chloroquine maculopathy in a patient on long-term chloroquine therapy for pulmonary sarcoidosis: a case report
DOI:
https://doi.org/10.31288/oftalmolzh202158487Keywords:
chloroquine maculopathy, case, diagnosis, treatment, mistakesAbstract
The article is on an important subject, chloroquine maculopathy associated with long-term use of chloroquine. Given that chloroquine has been widely used for the treatment of COVID-19, it is important to accumulate data on adverse reaction to chloroquine and its derivatives, especially in the populations of Europe where the practice of using these antimalarials was not so common as in Asia and Africa. The reported case exemplifies possible ocular side effects in patients on long-term use of chloroquine (Delagil).
References
1. Sharma OM. Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement. Arch Neurol. 1998 Sep;55(9):1248-54. https://doi.org/10.1001/archneur.55.9.1248
2. Lisitsyna TA, Kosheleva NM. [Antimalarial drugs in the therapy of systemic lupus erythematosus: present, past and future]. Sovremennaia revmatologiia. 2010;2:81-7. Russian.https://doi.org/10.14412/1996-7012-2010-608
3. Mehra MR, Ruschitzka F, Patel AM. Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020 Jun 5.https://doi.org/10.1016/S0140-6736(20)31180-6
4. Marmor MF, Kellner U, Lai TY, et al. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology. 2016 Jun;123(6):1386-94.https://doi.org/10.1016/j.ophtha.2016.01.058
5. World Health Organization. Medicines: safety of medicines-adverse drug reactions. Fact sheet no. 293. October 2008. Available at: http://www.who.int/mediacentre/factsheets/fs293/en/.
6. Kiely PDW, Brown AK, Edwards CJ, et al. Contemporary treatment principles for early rheumatoid arthritis: a consensus statement. Rheumatology (Oxford). 2009 Jul;48(7):765-72.https://doi.org/10.1093/rheumatology/kep073
7. Avina-Zubieta JA, Galiando-Rodrignez G, Newman S, et al. Long term effectiveness of antimalarial drugs in rheumatic diseases. Ann Rheum Dis. 1998 Oct;57(10):582-7.https://doi.org/10.1136/ard.57.10.582
8. Ruiz-Irastozza G, Ramos-Casals M, Brito-Zeron P, Khamastra MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010 Jan;69(1):20-8.https://doi.org/10.1136/ard.2008.101766
9. Rynes RI. Antimalarial drugs in the treatment of rheumatoiogical diseases. Brit J Rheum. 1997 Jul;36(7):799-805.https://doi.org/10.1093/rheumatology/36.7.799
10. Cambiaggi A. Unusual ocular lesions in a case of systemic lupus erythematosus. AMA Arch Ophthalmol. 1957 Mar;57(3):451-3.https://doi.org/10.1001/archopht.1957.00930050463019
11. Kazaryan AA, Ponomareva EN. [Ophthalmic manifestations of chloroquine toxicity: a case report]. Klinicheskaia praktika. 2011;2:12-21. Russian. https://doi.org/10.17816/clinpract2212-21
12. Yam JC, Kwok AK. Ocular toxicity of hydroxychloroquine. Hong Kong Med J. 2006 Aug;12(4):294-304.
13. Tehrani R, Ostrowski RA, Hariman R, Jay WM. Ocular toxicity of hydroxychloroquine. Semin Ophthalmology. May-Jun 2008;23(3):201-9.https://doi.org/10.1080/08820530802049962
14. Shearer RV, Dubois EI. Ocular changes induced by long-term hydroxychloroquine (Plaquenil) therapy. Am J Ophtalmol. 1967 Aug;64(2):245-52.https://doi.org/10.1016/0002-9394(67)92518-4
15. Duncker G, Schmiederer M, Bredehorn T. Chloroquine-induced lipidosis in the rat retina: a functional and morphological study. Opthalmologica. 1995;209(2):79-83.https://doi.org/10.1159/000310585
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Н. В. Малачкова , Т. Е. Козлова
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
